A share price of Outlook Therapeutics Inc [OTLK] is currently trading at $1.47, up 3.52%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The OTLK shares have lost -2.78% over the last week, with a monthly amount drifted -72.17%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Outlook Therapeutics Inc [NASDAQ: OTLK] stock has seen the most recent analyst activity on December 02, 2024, when Chardan Capital Markets downgraded its rating to a Neutral. Previously, BTIG Research upgraded its rating to Buy on March 27, 2024, and kept the price target unchanged to $50. On February 15, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $3 on the stock. Guggenheim upgraded its rating to a Buy. CapitalOne upgraded its rating to a Overweight but $5 remained the price target by the analyst firm on December 27, 2023. H.C. Wainwright downgraded its rating to Neutral for this stock on August 31, 2023, and downed its price target to $1. In a note dated August 31, 2023, Chardan Capital Markets downgraded an Neutral rating on this stock.
Outlook Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.87 and $12.85. Outlook Therapeutics Inc [NASDAQ: OTLK] shares were valued at $1.47 at the most recent close of the market.
Analyzing the OTLK fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -2.0, Equity is 1.47 and Total Capital is -13.51. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.39.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3771 points at the first support level, and at 1.2843 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.5464, and for the 2nd resistance point, it is at 1.6229.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Outlook Therapeutics Inc [NASDAQ:OTLK] is 1.07. As well, the Quick Ratio is 1.07, while the Cash Ratio is 0.75.
Transactions by insiders
Recent insider trading involved KENYON LAWRENCE A, Chief Financial Officer, that happened on Sep 26 ’24 when 5000.0 shares were purchased. Director, Haddadin Yezan Munther completed a deal on Mar 28 ’24 to buy 1882.0 shares. Meanwhile, CHIEF COMMERCIAL OFFICER Evanson Jeff bought 62484.0 shares on Mar 07 ’24.
